MedPageToday -- SAN FRANCISCO -- Postmenopausal women taking oral bisphosphonates for osteoporosis had almost a 50% reduction in the risk of colorectal cancer, according to data from a large cohort study. The case-control study, conducted among over 1,800 Israeli women, found that the magnitude of the risk reduction increased with length of time women were on antiresorptive therapy -- topping out at almost 80% with more than three years of bisphosphonate use, Gad Rennert, MD, of Carmel Medical Center in Haifa, and colleagues reported here at the Gastrointestinal Cancers Symposium.
